Participants were randomized to receive Padcev at 1.25 mg/kg on days 1 and 8 and Keytruda at 200 mg on day 1 for 3 cycles versus chemotherapy in the form of cisplatin or carboplatin plus gemcitabine ...

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.

Gene's lead asset shows high complete response rates in BCG-unresponsive NMIBC patients. Click here to read why ENGN stock is a Buy.

Regarding treatment, 69.2% of patients were treated with enfortumab vedotin monotherapy and 30.8% were treated with enfortumab vedotin plus pembrolizumab (Keytruda ... compared with 1.25 mg/kg (30.0%) ...

In contrast, the majority of patients without skin-related AEs received a dose of 1.25 mg/kg on cycle 10 ... who received prior avelumab and 77% who received prior pembrolizumab (Keytruda). This ...

In contrast, the majority of patients without skin-related AEs received a dose of 1.25 mg/kg on cycle 10 ... who received prior avelumab and 77% who received prior pembrolizumab (Keytruda). This ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in 2028, Jared Hopkins of The Wall Street Journal reports.

Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major pathological response in patients with resectable locally advanced head and ...